BMS-202, a PD-1/PD-L1 Inhibitor, Decelerates the Pro-fibrotic Effects of Fibroblasts Derived from Scar Tissues Via ERK and TGFβ1/Smad Signaling Pathways

Overview

Journal Immun Inflamm Dis

Specialties Allergy & Immunology
Infectious Diseases

Date 2022 Sep 28

PMID 36169254

Authors

Yuanyuan Cai

Min Xiao

Xinqing Li

Shanyu Zhou

Yangyang Sun

Wenyuan Yu

Tianlan Zhao

Affiliations

Soon will be listed here.

Abstract

Introduction: Hypertrophic scar (HS), a fibroproliferative disorder of the skin with some tumor-like properties, is closely related to dysregulated inflammation. PD-1/PD-L1 inhibitor is a promising medication for cancer therapy as its potent functions on adaptive immune response; whether it could be a candidate for HS therapy has aroused our interest. This study aimed to explore the effect and the mechanism of BMS-202, a PD-1/PD-L1 inhibitor, in HS.

Methods: Ten HS and adjacent normal skin tissues collected from HS patients were used to detect α-SMA, collagen I, and PD-L1 expression by Quantitative reverse transcription-polymerase chain reaction and western blot (WB) analysis. Fibroblasts derived from HS tissues (HFBs) were exposed to diverse concentrations of BMS-202, of which proliferation, migration, apoptosis, and collagen synthesis were evaluated by Cell Counting Kit-8, wound healing, terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End labeling, and [ H]-proline incorporation assays, respectively. The effect of BMS-202 on α-SMA and collagen I expression, and transforming growth factor beta 1 (TGFβ1)/Smad signaling in HFBs was also determined by WB and enzyme-linked immunosorbent assay.

Results: The expression level of PD-L1 was significantly elevated in both HS tissues and HFBs, which was positively correlated with α-SMA and collagen I expressions. BMS-202 exerted a significant suppression effect on the cell proliferation, migration, collagen synthesis, and α-SMA and collagen I expression of HFBs in a concentration-dependent way; but did not affect apoptosis. Finally, BMS-202 could reduce the phosphorylation of ERK1/2, Smad2, and Smad3, and the TGFβ1 expression once its concentration reached 2.5 nM.

Conclusion: BMS-202 effectively suppressed proliferation, migration, and extracellular matrix deposition of HFBs, potentially through the regulation of the ERK and TGFβ1/Smad signaling pathways.

Citing Articles

Myofibroblasts persist through immune privilege mechanisms to mediate oral submucous fibrosis: Uncovering the pathogenesis.

Sharma M, Shetty S, Soi S, Radhakrishnan R J Oral Biol Craniofac Res. 2024; 14(6):773-781.

PMID: 39502133 PMC: 11535754. DOI: 10.1016/j.jobcr.2024.10.008.

Preparation and effects of functionalized liposomes targeting breast cancer tumors using chemotherapy, phototherapy, and immunotherapy.

Zeng B, Pian L, Liu Y, Wang S, Wang N, Liu C J Nanobiotechnology. 2024; 22(1):558.

PMID: 39267061 PMC: 11391708. DOI: 10.1186/s12951-024-02838-1.

The effect of inflammatory cytokines on the risk of hypertrophic scar: a mendelian randomization study.

Qi S, Ma A, Lin H, Peng L, Deng E Arch Dermatol Res. 2024; 316(8):551.

PMID: 39167160 DOI: 10.1007/s00403-024-03303-7.

Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma.

Yang X, Wang W, Ji T Cell Death Dis. 2024; 15(3):186.

PMID: 38438374 PMC: 10912212. DOI: 10.1038/s41419-024-06553-5.

Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition.

Alharbi B, Qanash H, Binsaleh N, Alharthi S, Elasbali A, Gharekhan C Sci Rep. 2023; 13(1):7462.

PMID: 37156818 PMC: 10167246. DOI: 10.1038/s41598-023-34638-2.

References

Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A . PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019; 4(6). PMC: 6482997. DOI: 10.1172/jci.insight.125326. View

Julier Z, Park A, Briquez P, Martino M . Promoting tissue regeneration by modulating the immune system. Acta Biomater. 2017; 53:13-28. DOI: 10.1016/j.actbio.2017.01.056. View

Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J . Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018; 9(6):7204-7218. PMC: 5805548. DOI: 10.18632/oncotarget.23208. View

Massague J . Integration of Smad and MAPK pathways: a link and a linker revisited. Genes Dev. 2004; 17(24):2993-7. DOI: 10.1101/gad.1167003. View

Yu J, Hodge J, Oliva C, Neftelinov S, Hubbard-Lucey V, Tang J . Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov. 2020; 19(3):163-164. DOI: 10.1038/d41573-019-00182-w. View

Li Y, Yang J, Zheng Z, Hu D, Wang Z . Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF-β1/Smad and ERK pathways. J Cosmet Dermatol. 2020; 20(5):1374-1380. DOI: 10.1111/jocd.13842. View

Song Y, Guo B, Ma S, Chang P, Tao K . Naringin suppresses the growth and motility of hypertrophic scar fibroblasts by inhibiting the kinase activity of Akt. Biomed Pharmacother. 2018; 105:1291-1298. DOI: 10.1016/j.biopha.2018.06.103. View

Armour A, Scott P, Tredget E . Cellular and molecular pathology of HTS: basis for treatment. Wound Repair Regen. 2008; 15 Suppl 1:S6-17. DOI: 10.1111/j.1524-475X.2007.00219.x. View

Hu H, Chen D, Wang Y, Feng Y, Cao G, Vaziri N . New insights into TGF-β/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018; 292:76-83. DOI: 10.1016/j.cbi.2018.07.008. View

10.

Shirakami E, Yamakawa S, Hayashida K . Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020; 8:tkz003. PMC: 7175766. DOI: 10.1093/burnst/tkz003. View

11.

van der Veer W, Bloemen M, Ulrich M, Molema G, van Zuijlen P, Middelkoop E . Potential cellular and molecular causes of hypertrophic scar formation. Burns. 2008; 35(1):15-29. DOI: 10.1016/j.burns.2008.06.020. View

12.

Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A . The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012; 6(3):203-19. PMC: 3427235. DOI: 10.4161/cam.20377. View

13.

Zhang R, Zhu Z, Lv H, Li F, Sun S, Li J . Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer. Small. 2019; 15(49):e1903881. DOI: 10.1002/smll.201903881. View

14.

Wells A, Nuschke A, Yates C . Skin tissue repair: Matrix microenvironmental influences. Matrix Biol. 2015; 49:25-36. PMC: 4753148. DOI: 10.1016/j.matbio.2015.08.001. View

15.

Glim J, Beelen R, Niessen F, Everts V, Ulrich M . The number of immune cells is lower in healthy oral mucosa compared to skin and does not increase after scarring. Arch Oral Biol. 2014; 60(2):272-81. DOI: 10.1016/j.archoralbio.2014.10.008. View

16.

Burch M, Zheng W, Little P . Smad linker region phosphorylation in the regulation of extracellular matrix synthesis. Cell Mol Life Sci. 2010; 68(1):97-107. PMC: 11115152. DOI: 10.1007/s00018-010-0514-4. View

17.

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

18.

Li-Tsang C, Lau J, Chan C . Prevalence of hypertrophic scar formation and its characteristics among the Chinese population. Burns. 2005; 31(5):610-6. DOI: 10.1016/j.burns.2005.01.022. View

19.

Sun G, Li H, Zhan Y, Zhang X, Pan L, Chen Y . SnoN residue (1-366) attenuates hypertrophic scars through resistance to transforming growth factor-β1-induced degradation. Lab Invest. 2019; 99(12):1861-1873. DOI: 10.1038/s41374-019-0302-1. View

20.

Colak S, Ten Dijke P . Targeting TGF-β Signaling in Cancer. Trends Cancer. 2017; 3(1):56-71. DOI: 10.1016/j.trecan.2016.11.008. View